Review Article

Journal of Nuclear Cardiology

, Volume 20, Issue 2, pp 284-288

Regadenoson: A focused update

  • Gopal GhimireAffiliated withDivision of Cardiovascular Diseases, University of Alabama at Birmingham
  • , Fadi G. HageAffiliated withDivision of Cardiovascular Diseases, University of Alabama at BirminghamSection of Cardiology, Birmingham Veteran’s Administration Medical Center Email author 
  • , Jaekyeong HeoAffiliated withDivision of Cardiovascular Diseases, University of Alabama at Birmingham
  • , Ami E. IskandrianAffiliated withDivision of Cardiovascular Diseases, University of Alabama at Birmingham

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Since its approval by the Food and Drug Administration in 2008, regadenoson has become the most commonly used vasodilator in the United States. Previous reviews have summarized the pre-clinical and clinical data on the use of regadenoson for myocardial perfusion imaging (MPI). Since then, data have emerged on the safety of this agent in special groups of patients such as those with chronic kidney disease, airway disease (asthma and chronic obstructive pulmonary disease), and liver disease. There has also been recent interest in the use of regadenoson in hybrid protocols with exercise as a way to improve patient tolerance and image quality. Finally, although regadenoson was approved for clinical use based on the agreement rate of regadenoson MPI and adenosine MPI with regards to perfusion abnormalities, data are now available on the prognostic data derived from regadenoson MPI. We will briefly summarize these recent reports here in a focused update on the use of regadenoson for MPI.

Keywords

Regadenoson pharmacological stress testing adenosine SPECT